Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nova Mentis Life Science Corp. C.LIB

Healthcare Drug Manufacturers - Major Cannabis
Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich dominant cultivars cured to perfection.


CSE:LIB - Post by User

Nova Mentis Life Science Corp. > News on the docket
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by LANk655on Aug 22, 2018 8:59am
90 Views
Post# 28497890

RE:RE:RE:News on the docket

RE:RE:RE:News on the docket
if 64 trials are required, could there be some sort of "piggy back" deal wherein more iterations from another companies findings are combined to compile the 64 required? If so, are there that many different findings out there from another company that could be poised to take a partner/potential buy out by lib to obtain the remaining trials?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities